80后哈工大博士，干出运动医学龙头，冲刺IPO

Core Viewpoint - Tianxing Medical is a leading domestic company in the field of sports medicine, focusing on minimally invasive surgical products and aiming for a public listing on the Hong Kong Stock Exchange after multiple attempts [3][4]. Company Overview - Tianxing Medical specializes in medical devices for sports medicine, with core products including implants and surgical equipment for arthroscopic surgeries [3]. - The company has established a presence in over 3,000 hospitals in China and exports to more than 50 countries [3]. Financial Performance - Revenue increased from 147 million RMB in 2022 to 327 million RMB in 2024, with a compound annual growth rate (CAGR) of 49.1% [25]. - In the first three quarters of 2025, revenue reached 273 million RMB, with a net profit of 89.9 million RMB [25]. Market Position - As of 2024, Tianxing Medical holds a 6.5% market share, ranking as the fourth largest sports medicine device provider in China and the largest domestic provider [3][4]. - The sports medicine market in China is projected to grow from 5.4 billion RMB in 2024 to 12.1 billion RMB by 2030, with a CAGR of 14.3% [35]. Product Development - The company has developed 62 registered products, the highest number among domestic sports medicine companies, including 27 Class III and 24 Class II medical devices [24]. - Tianxing Medical's products are characterized by innovative technologies, such as absorbable implants, which are priced significantly lower than foreign counterparts [23]. Competitive Landscape - The market is dominated by international giants, but the introduction of national procurement policies has reduced foreign market share from 80% to around 50%, creating opportunities for domestic manufacturers [35][36]. - The company is positioned to benefit from favorable policies that expedite product approvals and enhance reimbursement processes for domestic devices [36]. Future Prospects - Tianxing Medical is expanding its product line to include surgical robots and AI-driven rehabilitation systems, aiming to provide comprehensive treatment and recovery solutions [31][40]. - The company is also exploring regenerative medicine, indicating a strategic move towards a more integrated business model [31].